Trial reportPediatric nephrology (Berlin, Germany)2003
Antiproteinuric effects of enalapril and losartan: a pilot study.
Trial report in Pediatric nephrology (Berlin, Germany), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pharmacological interventions for hypertension in children.The Cochrane database of systematic reviews · 2014Pooled it
- Protein restriction for children with chronic renal failure.The Cochrane database of systematic reviews · 2007Pooled it
- Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.Pediatric nephrology (Berlin, Germany) · 2011Trial
- Randomized, double-blind, controlled study of losartan in children with proteinuria.Clinical journal of the American Society of Nephrology : CJASN · 2010Trial
- Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2006Trial
- Effect of renal function on antihypertensive drug safety and efficacy in children.Pediatric nephrology (Berlin, Germany) · 2018Article
- Development of tandem mass spectrometry-based creatinine measurement using dried blood spot for newborn mass screening.Pediatric research · 2017Article
- Congenital Nephrotic Syndrome - Finish Type.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2016Article
- Evidence-based guidelines for the management of hypertension in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2015Review
- KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013Article
- Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Article
- Chapter 6: Blood pressure management in children with CKD ND.Kidney international supplements · 2012Article
- Association of angiotensin-converting enzyme gene I/D polymorphism with steroid responsiveness in childhood nephrotic syndrome.Indian journal of nephrology · 2011Article
- Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2010Review
- Diabetic nephropathy in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2008Review
- Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?Pediatric nephrology (Berlin, Germany) · 2004Review
- Future pharmacologic agents for treatment of heart failure in children.Pediatric cardiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this randomized double-blind crossover trial we compared the antiproteinuric effects of enalapril and losartan in six children with proteinuria and underlying renal injury. The primary endpoint was reduction in proteinuria during therapy. The study had two 8-week on-drug arms, with a 4-week washout period between. Baseline proteinuria was similar, enalapril 87 mg/m(2) per hour and losartan 77 mg/m(2) per hour. The mean reduction in proteinuria with enalapril was 48% (37%-57%) with a standard error of the mean of 3%; with losartan it was 31% (14%-52%) with a standard error of the mean of 7%. Although there was a significant reduction in proteinuria with the use of both drugs, the difference in reduction of proteinuria, 48% versus 31%, was not considered clinically significant. Potassium remained below 4.5 mmol/l in all patients. No patient's creatinine rose more than the standard deviation of our assay. Blood pressure (BP) control was acceptable in four of the six patients; two patients had persistently elevated or increased BP on each drug. Side effects were minimal; none requiring withdrawal, one requiring dose reduction. Studies have shown that angiotensin converting enzyme inhibitors can reduce proteinuria in children with renal disorders. No studies to date have examined the reduction of proteinuria achieved by angiotensin receptor blockers. Our study, although small, suggests that angiotensin receptor blockers may reduce proteinuria as effectively, and as safely, as angiotensin converting enzyme inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.